Overview
GeneResponse Technologies is a pioneering biotech startup based in Saudi Arabia focused on revolutionizing the field of personalized medicine through advanced gene therapies. With an increasing global demand for tailored healthcare solutions, our mission is to develop innovative therapies that leverage genetic information to improve patient outcomes. Over the past year, we have successfully completed preclinical trials for our first product, a gene-editing therapy targeting a rare genetic disorder, which has shown promising results. Our advanced platform utilizes CRISPR technology and AI-driven analytics to optimize therapy design, making our approach both effective and efficient. We are now at a pivotal stage in our growth, and to propel our developments forward, we are seeking $190,000 in investment. This funding will enable us to scale our operations, accelerate our research timelines, and prepare for clinical trials. Our team consists of experienced scientists and industry veterans who have a track record in biotech innovation. We have established essential partnerships with leading research institutions and have begun to attract attention from potential strategic partners. How…
Use of funds
The $190,000 will be allocated as follows: 50% for R&D to enhance our gene therapy platform, 30% for regulatory compliance and clinical trial preparation, and 20% for operational expenses such as team expansion and lab infrastructure improvements.
Open case
Open this case to get the detailed business plan and direct contact with the founder or seeker.